Hyperkalaemia Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | AstraZeneca, Ardelyx, Vifor Pharma, Zeria Pharmaceutical

Hyperkalaemia Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | AstraZeneca, Ardelyx, Vifor Pharma, Zeria Pharmaceutical
Delveinsight Business Research LLP
Hyperkalaemia Market size in the seven major markets was approximately USD 1,198 million in 2021, which is further expected to increase by 2032. As per DelveInsight, the Hyperkalaemia Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Hyperkalaemia and the launch of new therapies in the market.

DelveInsight’s “Hyperkalaemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hyperkalaemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Hyperkalaemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hyperkalaemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hyperkalaemia: An Overview

Hyperkalemia is defined as a high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death.

Hyperkalemia is defined as a serum potassium concentration that is equal to or greater than 5.5 mEq/L from a non-hemolyzed whole blood sample. The normal potassium level in the blood is 3.5-5.0 mEq/L. Furthermore, it can be classified according to serum potassium into mild (5.5–6.5 mmol/L), moderate (6.5–7.5 mmol/L) and severe (>7.5 mmol/L) hyperkalemia. Often hyperkalemia is asymptomatic, but at times they are often nonspecific such as heart palpitations, nausea, weakness, or paresthesia. Common acute manifestations of significant hyperkalemia include muscle weakness and ECG changes, with the latter having the potential to progress to a life-threatening arrhythmia.

Risk factors for hyperkalemia include several conditions such as chronic kidney disease, diabetes, congestive heart failure, and certain medications that disrupt the potassium balance. Also, males are found to suffer more than females with Hyperkalemia.

Hyperkalaemia Market Key Facts

  • In 2021, the total diagnosed prevalent cases of Hyperkalemia were estimated to be approximately 5,517,000+ cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 2.8% during the study period (2019–2032).

  • Among the 7MM, the United States accounted for nearly 79% of the total diagnosed prevalent cases of Hyperkalemia in the 7MM in the year 2021 which is expected to increase further by 2032.

  • Among EU4 and the United Kingdom, Germany had the highest total diagnosed prevalent cases of Hyperkalemia with approximately 212,445 cases in 2021, while Spain had the lowest diagnosed prevalent population of Hyperkalemia with approximately 15,918 cases in 2021.

  • According to the study conducted by Kashihara et al. (2019) titled “Hyperkalemia in Real-World Patients under Continuous Medical Care in Japan,” hyperkalemia prevalence was 67.9/1,000 and increased in patients with chronic kidney disease (CKD), heart failure, and renin-angiotensin-aldosterone system inhibitor (RAASi) use. The mean age was found to be 72.4±13.0 years, and 55% were men.

Hyperkalaemia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hyperkalaemia pipeline therapies. It also thoroughly assesses the Hyperkalaemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Hyperkalaemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Hyperkalaemia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Hyperkalaemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hyperkalaemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Hyperkalaemia Epidemiology, Segmented as –

  • Prevalent cases of Hyperkalemia

  • Gender-specific prevalent cases of Hyperkalemia

  • Severity-specific prevalent cases of Hyperkalemia [Mild, Moderate, and Severe]

  • Prevalent cases of Hyperkalemia with associated risk factors (Chronic kidney disease (CKD), heart failure, diabetes, hypertension, and others)

  • Diagnosed and treatable cases of Hyperkalemia

Hyperkalaemia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hyperkalaemia market or expected to be launched during the study period. The analysis covers the Hyperkalaemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hyperkalaemia drugs based on their sale and market share.

The report also covers the Hyperkalaemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hyperkalaemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Hyperkalaemia Market Will Evolve and Grow by 2032 @ 


Hyperkalaemia Therapeutics Analysis

The treatment of hyperkalemia is directly related to the swiftness with which hyperkalemia has developed in an individual with the absolute level of hyperkalemia and the evidence of toxicity. The faster the potassium rises, the higher the level is, and the stronger will be the evidence of cardiotoxicity, resulting in the requirement for more aggressive therapy.

However, frequently used therapies for hyperkalemia may also be associated with morbidity. Therapeutics may include the simultaneous administration of insulin and glucose (associated with frequent dysglycemic complications), β-2 agonists (associated with potential cardiac ischemia and arrhythmias), hypertonic sodium bicarbonate infusion in the acidotic patient (representing a large hypertonic sodium load) and renal replacement therapy (effective but invasive). In addition, potassium-lowering drugs can cause a rapid decrease in serum potassium levels, leading to cardiac hyperexcitability and rhythm disorders. 

To further improve the treatment outlook, several major pharma and biotech companies are actively working in the Hyperkalaemia Therapeutics Market.

Hyperkalaemia Companies Actively Working in the Therapeutics Market Include

  • AstraZeneca

  • Ardelyx

  • Vifor Pharma

  • Zeria Pharmaceutical

And Many Others

Emerging and Marketed Hyperkalaemia Therapies Covered in the Report Include:

  • RDX013: Ardelyx

  • ZG-801/Patiromer (Zeria)

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Hyperkalaemia Competitive Intelligence Analysis

4. Hyperkalaemia Market Overview at a Glance

5. Hyperkalaemia Disease Background and Overview

6. Hyperkalaemia Patient Journey

7. Hyperkalaemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Hyperkalaemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Hyperkalaemia Unmet Needs

10. Key Endpoints of Hyperkalaemia Treatment

11. Hyperkalaemia Marketed Therapies

12. Hyperkalaemia Emerging Drugs and Latest Therapeutic Advances

13. Hyperkalaemia Seven Major Market Analysis

14. Attribute Analysis

15. Hyperkalaemia Market Outlook (In US, EU5, and Japan)

16. Hyperkalaemia Companies Active in the Market

17. Hyperkalaemia Access and Reimbursement Overview

18. KOL Views on the Hyperkalaemia Market

19. Hyperkalaemia Market Drivers

20. Hyperkalaemia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Optic Neuritis Market

“Optic Neuritis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Optic Neuritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Optic Neuritis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices